Skip to content
OpenCapital
Get started

Jazz Pharmaceuticals JAZZ Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period at other companies

General Motors logo
General MotorsGM
3.9M+14.7%
RBC Bearings logo
RBC BearingsRBC
46.1K+3.9%
Arthur J. Gallagher logo
Arthur J. GallagherAJG
4.1M—
StoneX Group Inc. logo
StoneX Group Inc.SNEX
407.1K+71.3%
General Motors logo
General MotorsGM
15M+29.3%
Cherry Hill Mortgage Investment logo
Cherry Hill Mortgage InvestmentCHMI
14.5K—

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod.

The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, expirations in period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, expirations in period?
Jazz Pharmaceuticals (JAZZ) reported share-based compensation arrangement by share-based payment award, options, expirations in period of 340K in Q4 2025.
How has Jazz Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, expirations in period changed year-over-year?
Jazz Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, expirations in period decreased by 36.6% year-over-year, from 536K to 340K.
What does share-based compensation arrangement by share-based payment award, options, expirations in period mean?
The number of stock options that became worthless because they were not exercised.
How do you interpret share-based compensation arrangement by share-based payment award, options, expirations in period?
A high number of expirations suggests that the company's stock price did not meet the performance expectations set at the time of the option grants.
How does share-based compensation arrangement by share-based payment award, options, expirations in period compare across companies?
Varies significantly based on historical stock price performance and grant timing.